Biotechnology and Pharmaceutical Services Outsourcing Market study provides detailed information on market upcoming trends, new business development, drivers, capacities, and technologies. It covers ...
On Monday, April 24, The Biotechnology Study Center of NYU School of Medicine will hold its annual awards symposium to honor three outstanding pioneers in neurobiology and cognition. The Dart/NYU ...
The Southeast Asian Regional Center for Graduate Study and Research in Agriculture (Searca) participated in the recent ...
A study offering newborn babies "cutting-edge genomic screening" with the hope of identifying rare but treatable illnesses could be "life-changing" for families, doctors have said. Gloucester Royal ...
NEW YORK -- Investors accurately forecasted the rebound of the biotechnology industry, but underestimated the degree to which positive clinical trial data would drive the sector higher, according to ...
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% ...
TipRanks on MSN
MAIA Biotechnology Expands Phase 2 Study in Romania
MAIA Biotechnology, Inc. ( ($MAIA) ) has shared an announcement. On November 20, 2025, MAIA Biotechnology announced that its CEO, Vlad Vitoc, ...
Unity Biotechnology, Inc. (NASDAQ:UBX) stock plummeted on Monday after the company released results from its latest study. The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients ...
WESTFORD – Students in the Biotechnology program at Nashoba Valley Technical High School are getting their feet wet this year … well, their hands, more accurately. To keep up with the state’s ...
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, ...
Vir Biotechnology Inc. (NASDAQ: VIR) shares jumped on Tuesday after the firm announced, in conjunction with GlaxoSmithKline PLC (NYSE: GSK), that they would be expanding their late-stage COVID-19 ...
The Phase 3 study testing the drug, VIR-7831, enrolled about 1,300 patients in North America, South America, and Europe. Those patients had Covid infection, but their disease had not yet progressed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback